Les bases biologiques de la prévention du cancer du poumon

Medecine/Sciences

Volumn 13, Issue 12, 1997, Pages 1465-1471

  Martinet, Yves ^a   Brambilla, Elisabeth ^b   Martin, Jean Pierre ^c   Martinet, Nadine ^c   Vignaud, Jean Michel ^d  

^a CHU NANCY BRABOIS   (France)

^b GRENOBLE UNIVERSITY HOSPITAL   (France)

^c INSERM   (France)

^d UNIVERSITY HOSPITAL OF NANCY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0343146931     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.4267/10608/581     Document Type: Article

References (40)

1. Gazdar AF, Bader S, HungJ, Kishimoto Y, Sekido Y, Sugio K, Virmani A, Carbone DP, Minna JD. Molecular genetic changes found in human lung cancer and its precursor lesions. In: Molecular genetic changes found in human lung cancer and its precursor lesions. New York, Cold Spring Harbor Laboratory, 1995:565-72.
2. Minna JD, Sekido Y, Fong K, Gazdar AF. Molecular biology of lung cancer. In : DeVita \T Jr., Hellman S, Rosenberg SA, eds. Molecular biology of cancer. Philadelphia: Lippincott, 1997: Chapitre 30.1.
3. Sozzi G, Veronese ML, Negrini M, Baffa R, Corticelli MG, Inoue H, Tornielli S, Pilotti S, Olita M, Huebner K, Croce CM. The HUT gene at 3pl4.2 is abnormal in lung cancer. Cell 1996; 85: 17-26.
4. HungJ, Kishimoto Y, Sugio K, Virmani A, Mclntire DD, Minna JD, Gazdar AF. Allelespecific chromosome 3p deletions occur at an early stage in the pathogenesis of lung carcinoma. JAMA 199o; 273: 558-63.
5. Kishimoto Y, Sugio K, Mitsudomi T, Oyama T, Virmani A, Mclntire DD, Gazdar AF. Allele specific loss of chromosome 9p in preneoplastic lesions accompanying nonsmall cell lung cancers. / Natl Cancer Insl 1995; 87: 1224-9.
6. Klein N, Vignaud JM, Sadmi M, Plénat F, BorrellyJ, Duprez A, Martinet Y, Martinet N. Squamous metaplasia expression of proto-oncogenes and P53 in lung cancer patients. Lab Invest 1993; 68: 26-32.
7. Thiberville L, Payne P, Vielkinds T, LeRiche I, Horsman D, Nouvel G, Palcic B, Lam S. Evidence of cumulative gene losses with progression of premalignant epithelial lesions to carcinoma of the bronchus. Cancer Res 1995; 55: 5133-9.
8. Vignaud JM, Marie B, Klein N, Plénat F, Pech M, Borrelly J, Martinet N, Dunrez A, Martinet Y. The role of platelet-derived growth factor production by tumor-associated macrophages in tumor stroma formation in lung cancer. Cancer Res 1994; 54: 5455-63.
9. Bolon I, Brambilla E, Vandenbunder B, Robert C, Lantuejoul S, Brambilla C. Changes in the expression of matrix proteases and of the transcription factor c-Ets-1 during progression of precancerous bronchial lesions. I jib Invest 1996; 75: 1-13.
10. Sclafani RA, Schauer IE. Cell cycle control and cancer: lessons from lung cancer, y Invest DennatollWG; 106: 1S-5S.
11. Schauer IE, Siriwardana S, Langan TA, Sclafani RA. Cyclin Dl overexpression vs. Rb inactivation: alternate mechanisms of growth control evasion in non-small cell and small cell lung cancer. Proc A'n// Acad Sri ££-11994; 91: 7827-31.
12. Shapiro GI, Park JE, Edwards CD, Mao L, Merlo A, Sidransky D. Multiple mechanism of pl6'-v inactivation in non-small cell lung cancer cell lines. Cancer Res 1995 ; 55: 6200-9.
13. Couver V, Gazzeri S, Brambilla E, Bolon ' I, Moro D, Perron P, Benabid AL, Brambilla C. Loss of heterozygosity at the RB locus correlates with loss of RB protein in primary malignant neuro-endocrme lung carcinomas. IntJ Cancer 1994; 58: 818-24.
14. Lotan R, Xu XC, Lippman SM, Ro JY, Lee JS, Lee Hong K. Suppression of retinoic acid receptor βin premalignant oral lesions and its irpregulation by isotretinoin. NEnglJMed 1995; 332: 140a-10.
15. Seckl Ml, Higgins T, Widmer F, Rozengurt E. [DArg1, DTrp5'7'9, Leu"] Substance P : a novel and potent inhibitor of signal transduction and growth in vitro and in vivo in small cell lung cancer cells. Cancer Res 1997;57:51-4.
16. Moustafa A, Tsao MS, BatteyJF, Viallet I. Expression of the gastrin-releasing peptide receptor confers a growth response to bombesin in immortalized human bronchial epithelial cells. Cancer Res 1995; 55:1853-5.
17. Miller MJ, Martinez A, Unsworth EJ, Thiele CJ, Moody TW, Elsasser T, Cuttitta F. Adrenomedullin expression in human tumor cell lines, its potential role as an autocrine growth factor. / Biol Chem 1996; 271:2334>51.
18. Kuick R, AsakawaJ, Neel JV, Satoh C, Hanash SM. High yield of restriction fragment length polymorphisms in two-dimensional separations of human genomic DNA. Genomics 1995; 25: 345-53.
19. Mills NE, Fishman CL, Scholes J, Anderson SE, Rom ANTS', Jacobson DR. Detection of K-ras oncogene mutations in bronchoalveolar larage fluid for lung cancer diagnosis. JNatl CancerInst 1995; B7: 1056-60.
20. Mornex IF, Lena P, Loire R, Cozon G, Greenland T, Guiguen F, Jacquier MF, Cordier G. Lentivinis-inducea interstitial lung disease : pulmonary pathology in sheep spontaneously infected by the visna-inaedi virus. Vet Res 1994; 25: 478-88.
21. Houle B, Rochette-Egly C, Bradley WEG. Tumor-snppressive effect of the retinoic acid receptor βin human epidermoid lung cancer cells. Proc Natl Acad Sei USA 1993; 90:985-9.
22. Hill C. Mortalité liée au tabagisme. Rev PraH993; 43: 1209-13.
23. Benhamou S, Bonaïti-Pellié C. Susceptibilité au cancer bronchique: un exemple d'interaction génétique-environnement. Ann Biol Clin 1995; 53: 507-13.
24. Bouchardy C, Benhamou S, Dayer P. The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res 19%; 56: 251-3.
25. Alexandrie AK, Ingelman-Sundberg M, SeidegârdJ, Tornling G, Rannug A. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1 : a study on nost factors in relation to age at onset, gender and histological cancer types. Carcinogeimisl994; 15: 1785-90.
26. Soussi T, May P. Structural aspects of the p53 protein in relation to gene evolution: a second look./Mo/ Dial 1996; 260: 623-37.
27. Sozzi G, Miozzo M, Donghi R. Deletions of 17p and p53 mutations in preneoplastic lesions of the lung. Cancer Kfs 1992; 52: 6079-82.
28. Schlichtholz B, Tredaniel J, Lubin R, Zalcman G, Hirsch A, Soussi T. Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. BrJ Cancer 1994 ; 69:809-16.
29. ZhouJ, Mulshine JL, Unsworth EJ, Avis I, Cuttitta F, Treston A. Purification and characterization of a protein that permits early detection of lung cancer. Identification of the heterogeneous nuclear ribonucleoprotein-A2/Bl as the antigen for monoclonal antibody 703D4. / Bid Cliem 1996; 271: 10760-6.
30. Field JK, Neville EM, Ste\vart MP, Swift A, Liloglou T, RiskJM. Fractional allele loss data indicate genetic populations in the development of non-small cell lung cancer. BrJ Cancer 1996; 74: 1968-74.
31. Parkin DM, Sasco AJ. Lung cancer: worldwide \-ariation in occurrence and proportion attributable to tobacco use. Lung Cnnrcrl993;9: 1-16.
32. Mulshine JL. Fostering chemoprevention agent development: how to preceed? / Cell Biochem 1995; 22S: 254-9.
33. Wang ZY, Hong 1Y, Huang MT, Reuhl K, Conney AH, Yang CS. Inhibition of N-nitrosodiethylamine-and4-(methylnitrosamino)l-(3-pyridyl)-l-butanone-induced tumorigenesis m A/I mice by green tea and black tea. Cancer lies 1992; 52: 1943-7.
34. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh IP, Meyskons FL, Valanis B, Williams Jr. JH, Ijarhart S, Hammar S. Effects of a combination of beta-carotene and vitamin A on lung cancer and cardiovascular disease. NEnelj Med 1996; 334: 1150-5.
35. Tursz T, Le Cesne A, Baldeyrou P, Gautier E, Opolon P, Schatz C, Pavirani A, Courtney M, Lamy D, Ragot T, Saulnier P, Andremont A, Monier R, Perricaudet M, Le Chevallier T. Recombinant adenoviralmediated gene transfer: preliminary report of a phase I study in lung cancer patients./ Natl Cancer Inst 1996; 88: 1857-63.
36. Gazzeri S, Brambilla E, Caron de Fromentel C, Couver V, Moro D, Perron P, Berger F, Brambilla C. p53 genetic abnormal!-ties and Myc activation in human lung carcinoma. InlJ Cancer 1994; 58: 24-32.
37. Viallet J, Minna JD. Dominant oncogenes and tumor suppressor genes in the patliogenesis of lung cancer. Am J Rest) Cell IUomon990;2:22o-32.
38. Volm M, Efferth T, Mattern J. Oncoprotein (c-erbBl, c-erbB2, c-fos) and suppressor gene product (p53) expression in squamous cell carcinomas of the lung. Clinical and biological correlations. Anticancer Res 1992; 12: 11-20.
39. Nakanishi Y, Mulshine J, Kasprzyk P, Natale R, Maneckjee R, Avis I, Treston A, Gazdar A, Minna J, Cuttitta F. Insulin-like growth factor-1 can stimulate the proliferation of human small cell lung cancer lines. / Clin Investi 988 ; 82: 354-9.
40. Krystal GW, Hines SJ, Organ CP. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 1996; 56: 370-6.